N-碘苯并三唑 | 68407-95-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: N-碘苯并三唑
• 英文名称: N-iodobenzotriazole
• 英文别名: 1-Iodobenzotriazole
• CAS: 68407-95-4
• 化学式: C₆H₄IN₃
• 分子量: 245.022
• InChiKey: YATUXKFWIIHFTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-碘苯并三唑 在 碘甲烷 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以10%的产率得到1-甲基苯并三唑
  参考文献：
  名称：

  Kurenkov, A. A.; Pevzner, M. S., Russian Journal of Organic Chemistry, 1995, vol. 31, # 8, p. 1122 - 1124

  摘要：

  DOI：
• 作为产物：
  描述：

  T406石油添加剂 在 一氯化碘 、 三丁基氧化锡 作用下， 生成 N-碘苯并三唑
  参考文献：
  名称：

  锡（IV）介导的N-卤化物的合成

  摘要：

  某些代表性的N-卤代化合物，例如N-溴丁二酰亚胺，N-碘丁二酰亚胺，N-溴邻苯二甲酰亚胺，N-碘邻苯二甲酰亚胺，N-碘苯并咪唑和N-碘苯并三唑已通过母体NH物种形成的中间体以高收率和中性和温和条件合成和双（三正丁基锡）氧化物。氧化锡以可回收的三正丁基卤化锡的形式回收。

  DOI：

  10.1016/s0022-328x(00)99321-5

文献信息

• Tin(IV) mediated synthesis of N-halo compounds
  作者：R. Soundararajan、S. Krishnamurthy、Vilanoor S. Srinivasan、T.R. Balasubramanian

  DOI：10.1016/s0022-328x(00)99321-5

  日期：1983.10

  Some representative N-halo compounds like N-bromosuccinimide, N-iodosuccinimide, N-bromophthalimide, N-iodophthalmide, N-iodobenzimidazole and N-iodobenzeotriazole have been synthesised in good yields and neutral and mild conditions via an intermediate formed from the parent NH species and bis(tri-n-butyltin) oxide. The tin oxide is recovered as recyclable tri-n-butyltin halide.

  某些代表性的N-卤代化合物，例如N-溴丁二酰亚胺，N-碘丁二酰亚胺，N-溴邻苯二甲酰亚胺，N-碘邻苯二甲酰亚胺，N-碘苯并咪唑和N-碘苯并三唑已通过母体NH物种形成的中间体以高收率和中性和温和条件合成和双（三正丁基锡）氧化物。氧化锡以可回收的三正丁基卤化锡的形式回收。
• [EN] COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY<br/>[FR] COMPOSÉS INHIBANT L'ACTIVITÉ ENZYMATIQUE DE LA KINASE À RÉPÉTITIONS RICHES EN LEUCINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015026683A1

  公开（公告）日：2015-02-26

  The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及氮杂吲哚化合物，这些化合物是LRRK2激酶的有效抑制剂，并且在治疗或预防LRRK2激酶参与的疾病，如帕金森病中有用。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗LRRK2激酶参与的疾病中使用这些化合物和组合物。
• METHOD FOR OBTAINING 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE
  申请人：ABIDOPHARMA PL SP. Z.O.O.

  公开号：US20140113902A1

  公开（公告）日：2014-04-24

  A method for preparing 5-amino-2,3-dihydrophthalazine-1,4-dione salts with alkali metals of the formula II, pharmaceutical compositions including such salts, and their application in medicine. The sodium salt may be used for treatment of heart diseases, pancreas diseases and diabetes as well as optionally in combination with lithium salt for treatment of the nervous system diseases. where M represents Li, Na, K

  一种制备配有碱金属的5-氨基-2,3-二氢邻苯二酮盐的方法，其化学式为II，制备包括这种盐的药物组合物，并将其应用于医学。钠盐可用于治疗心脏疾病、胰腺疾病和糖尿病，也可以与锂盐结合用于治疗神经系统疾病。其中，M代表Li，Na，K。
• COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY
  申请人：DEMONG Duane

  公开号：US20160200722A1

  公开（公告）日：2016-07-14

  The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及一种阿扎印唑化合物，其是LRRK2激酶的有效抑制剂，可用于治疗或预防LRRK2激酶参与的疾病，如帕金森病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗LRRK-2激酶参与的疾病中使用这些化合物和组合物。
• Amphiphilic Block Copolymer And Preparation Method Thereof And Micellar Drug-Loading System Formed By Same With Antitumor Drug
  申请人：LIU Ke

  公开号：US20150283246A1

  公开（公告）日：2015-10-08

  The present invention relates to a novel amphiphilic block copolymer and the preparation method thereof, as well as a micellar drug-loaded system formed by said copolymer and an anti-tumor drug. Said amphiphilic block copolymer comprises a hydrophilic segment and a hydrophobic segment, and the end group of said hydrophobic segment is end-capped with a hydrophobic group. Methoxypolyethylene glycol (or polyethylene glycol)-polyester block copolymer which has recognized safety is used as a fundamental material of the amphiphilic block copolymer of the present invention, and the terminal hydroxyl group of the polyester segment is modified with a hydrophobic group, whereby the compatibility between the drug molecule and the hydrophobic segments of the block copolymer is improved, and the interaction therebetween is enhanced. Moreover, a larger space for accommodating the drug molecules is provided. Said micelles are more effective in restricting the drug molecules inside the micellar core and preventing the drug from dissolved out of the micelles. Therefore, a drug-loaded micelle with high stability is obtained.

  本发明涉及一种新型的两亲性嵌段共聚物及其制备方法，以及由该共聚物和抗肿瘤药物形成的微胶束药物载药系统。该两亲性嵌段共聚物包括亲水性段和疏水性段，疏水性段的末端基团被疏水基团封端。本发明的两亲性嵌段共聚物的基础材料采用了已经被认可为安全的甲氧基聚乙二醇（或聚乙二醇）-聚酯嵌段共聚物，并且聚酯段的末端羟基被疏水基团修饰，从而提高了药物分子与嵌段共聚物的疏水性段之间的相容性和相互作用，同时提供了更大的容纳药物分子的空间。这些微胶束更有效地限制了药物分子在微胶束核心内的扩散和溶解，因此获得了高稳定性的药物载药微胶束。